Tolfenamic Acid

Tolfenamic acid is a nonsteroidal anti-inflammatory drug belonging to the fenamate class that has been widely used in food animal medicine throughout Europe and other regions for several decades. This medication provides effective anti-inflammatory, analgesic, and antipyretic activity in cattle, pigs, and other livestock species, making it a valuable tool for managing pain and inflammation associated with various disease conditions and husbandry procedures. Tolfenamic acid has earned recognition for its favorable efficacy and safety profile in food-producing animals.

The mechanism of action of tolfenamic acid involves inhibition of cyclooxygenase enzymes, blocking the conversion of arachidonic acid to prostaglandins that mediate inflammation, pain, and fever. Like other NSAIDs, tolfenamic acid reduces the production of inflammatory prostaglandins at sites of tissue injury and infection, providing symptomatic relief while the underlying condition is addressed through appropriate therapy. The drug also has effects on leukotriene synthesis and may modulate other inflammatory pathways, contributing to its overall anti-inflammatory activity.

Tolfenamic acid is available primarily as an injectable solution for intramuscular, intravenous, or subcutaneous administration in food animals. The injectable formulation allows for precise dosing and rapid onset of action, making it suitable for treatment of acute conditions and situations requiring immediate pain relief. Some oral formulations are available for companion animal use, but injectable preparations are the standard in livestock medicine. The drug demonstrates good bioavailability and achieves therapeutic tissue concentrations relatively quickly after administration.

From a regulatory standpoint, tolfenamic acid is approved for use in food-producing animals in the European Union, United Kingdom, and numerous other countries, with established maximum residue limits and withdrawal periods for meat and milk. Availability in other regions, including North America, may be limited or require importation under special provisions. Veterinarians should verify the regulatory status of tolfenamic acid in their jurisdiction before prescribing and ensure that appropriate withdrawal times are observed for all treated animals destined for food production.

Tolfenamic acid is indicated for the treatment of fever, pain, and inflammation associated with respiratory disease in cattle and pigs. Bovine respiratory disease complex represents one of the most common and economically significant disease syndromes in cattle production, and the accompanying fever, depression, and respiratory distress benefit significantly from anti-inflammatory therapy. Administration of tolfenamic acid alongside appropriate antimicrobial treatment helps reduce fever, improve appetite, and support faster clinical recovery. Similarly, respiratory infections in swine cause substantial welfare and economic impacts that respond to combined antimicrobial and anti-inflammatory therapy.

Mastitis treatment in dairy cattle frequently incorporates tolfenamic acid to address the intense inflammation and pain associated with udder infection. Clinical mastitis causes significant suffering, reduces milk production, and may cause permanent udder damage if the inflammatory response is not adequately controlled. Tolfenamic acid helps reduce udder inflammation, alleviates the pain that discourages normal suckling behavior in beef calves or machine milking in dairy operations, and may improve cure rates when used as part of comprehensive mastitis therapy. The drug's antipyretic effect is also beneficial, as mastitis often causes systemic fever.

Metritis and other reproductive tract infections in cattle represent additional indications for tolfenamic acid therapy. Post-partum uterine infections cause fever, reduced appetite, decreased milk production, and impaired fertility if not adequately addressed. The anti-inflammatory effects of tolfenamic acid help manage the systemic signs of infection while appropriate antimicrobial therapy addresses the bacterial cause. Similarly, other inflammatory conditions of the reproductive tract may benefit from adjunctive NSAID therapy to improve comfort and clinical outcomes.

Musculoskeletal disorders including lameness, arthritis, and traumatic injuries respond to tolfenamic acid treatment with reduced pain and inflammation. Lameness is a major welfare and economic concern in cattle production, affecting mobility, feed intake, and productivity. While addressing the underlying cause of lameness remains essential, pain management with NSAIDs such as tolfenamic acid improves animal comfort and supports recovery. Joint infections, tendon injuries, and other musculoskeletal conditions similarly benefit from anti-inflammatory therapy as part of a comprehensive treatment plan.

Post-operative pain management and procedural analgesia represent growing applications for tolfenamic acid in food animal practice. Surgical procedures, dehorning, castration, and other painful interventions cause significant discomfort that was historically undertreated in livestock. Modern animal welfare standards increasingly mandate appropriate pain management for these procedures, and tolfenamic acid provides effective analgesia when administered before or at the time of painful interventions. The drug's extended duration of action makes it suitable for providing post-operative comfort during the initial recovery period.

The recommended dosage of tolfenamic acid in cattle is typically 2 mg per kilogram of body weight, administered by intramuscular or intravenous injection. This dose can be repeated after 24 to 48 hours if clinical signs persist, though treatment duration should generally be limited to two to three doses unless otherwise directed by a veterinarian. For acute conditions with significant inflammation, the initial dose may be given intravenously for rapid onset of effect, with subsequent doses administered intramuscularly. Accurate weight estimation is essential for proper dosing, and scales or weight tapes should be used when available.

Swine dosing of tolfenamic acid follows similar guidelines, with 2 mg per kilogram administered intramuscularly. The injection site in pigs is typically the neck muscles, using appropriate needle size for the size of the pig being treated. Young pigs and piglets require careful dose calculation based on actual body weight rather than estimation. Treatment may be repeated after 24 hours if clinical improvement is insufficient, but prolonged treatment courses should be avoided without veterinary reassessment of the underlying condition.

The route of administration significantly affects the onset and duration of tolfenamic acid activity. Intravenous administration provides the most rapid onset of effect, typically within 15 to 30 minutes, making it preferred for animals with severe pain or high fever requiring immediate intervention. Intramuscular administration results in somewhat slower absorption but provides reliable drug delivery and may be more practical in field conditions. Subcutaneous administration is accepted for some products and offers an alternative injection site, though absorption characteristics may differ from intramuscular injection.

Proper injection technique is essential for ensuring drug efficacy and minimizing local reactions. Injections should be administered in approved anatomical sites using sterile needles of appropriate gauge and length for the species and injection route. For intramuscular administration in cattle, the neck muscles are preferred to avoid injection site lesions in valuable meat cuts. The injection site should be clean and dry, and the needle should be changed between animals to maintain sterility and prevent disease transmission. Maximum injection volumes should not exceed those specified on the product label for each injection site.

Treatment duration with tolfenamic acid should be limited to the shortest period necessary to achieve clinical improvement. While the drug is generally well tolerated, prolonged NSAID therapy increases the risk of adverse effects and is generally unnecessary for acute inflammatory conditions. Most labeled indications specify one to three treatments at 24 to 48 hour intervals. If clinical signs do not improve with initial treatment, veterinary reassessment is warranted to confirm the diagnosis and consider alternative or additional therapies.

Withdrawal times for tolfenamic acid must be strictly observed before treated animals or their products enter the food supply. Meat withdrawal times are typically 12 to 21 days depending on the specific product, species, and regional regulations. Milk withdrawal times for dairy cattle are generally 24 to 36 hours but vary by product and must be verified on the specific product label. Producers must maintain accurate treatment records documenting the identity of treated animals, date of treatment, dose administered, and calculated withdrawal date. Consultation with the Food Animal Residue Avoidance Databank or equivalent regional resource is recommended when withdrawal information is uncertain.

Tolfenamic acid is generally well tolerated in food-producing animals when used according to label recommendations. The drug has been used for decades in cattle and pig production with a good overall safety record. However, as with all NSAIDs, adverse effects can occur, and producers and veterinarians should be aware of the potential for both local and systemic reactions. Most side effects are mild and transient, but serious reactions are possible, particularly with improper use or in susceptible individuals.

Injection site reactions are among the most commonly reported adverse effects of tolfenamic acid. Local swelling, pain, or tissue irritation may occur at the site of intramuscular or subcutaneous injection. These reactions are usually mild and resolve within a few days without specific treatment. Proper injection technique, including use of appropriate needle size, adherence to recommended injection volumes, and selection of approved injection sites, helps minimize the occurrence and severity of local reactions. Injection site lesions are of particular concern in meat animals, which is why neck injection is preferred over hindquarter sites.

Gastrointestinal effects may occur with tolfenamic acid use, though the incidence appears lower than with some other NSAIDs. Reduced appetite, mild digestive disturbances, or changes in fecal consistency may be observed in some treated animals. Severe gastrointestinal complications such as ulceration and bleeding are uncommon at recommended doses but may occur with overdosing, prolonged treatment, or in animals with pre-existing gastrointestinal disease. Monitoring appetite and fecal output during treatment helps identify animals experiencing gastrointestinal adverse effects.

Renal effects represent a potential concern with any NSAID, including tolfenamic acid. Prostaglandins play an important role in maintaining renal blood flow, particularly in animals that are dehydrated or have compromised cardiovascular function. Administration of tolfenamic acid to animals in these conditions may impair kidney function. Animals should be adequately hydrated before receiving tolfenamic acid, and the drug should be used cautiously in animals with pre-existing kidney disease or conditions that may compromise renal perfusion. Signs of renal adverse effects may include decreased urine output, changes in urine character, or signs of fluid retention.

Allergic or hypersensitivity reactions to tolfenamic acid are rare but possible. Signs may include facial swelling, hives, respiratory distress, or in severe cases, anaphylaxis. Animals with a history of adverse reactions to tolfenamic acid or other NSAIDs should not receive the drug. Any signs of hypersensitivity reaction require immediate treatment discontinuation and appropriate supportive care. The occurrence of any unexpected or severe adverse reaction should be reported to the product manufacturer and relevant regulatory authorities.

Tolfenamic acid is contraindicated in animals with known hypersensitivity to tolfenamic acid or other NSAIDs. Prior adverse reaction to any NSAID, including signs of allergic response or severe gastrointestinal effects, should prompt careful consideration before using tolfenamic acid. While cross-reactivity between different NSAIDs is not universal, the possibility exists, and alternative pain management strategies should be considered for animals with NSAID sensitivity history.

Animals with active gastrointestinal ulceration or bleeding should not receive tolfenamic acid. The inhibition of protective prostaglandins in the gastrointestinal tract may worsen existing lesions and delay healing. Similarly, animals with a history of gastrointestinal ulcers should be treated with caution, and the potential benefits of tolfenamic acid therapy must be weighed against the risk of recurrent gastrointestinal complications. Signs of gastrointestinal bleeding, including dark or bloody feces, should prompt immediate evaluation before initiating NSAID therapy.

Significant renal or hepatic impairment represents a contraindication to tolfenamic acid use. Animals with known kidney disease should not receive NSAIDs due to the risk of further renal damage. Similarly, severe liver dysfunction may impair drug metabolism and increase the risk of toxicity. Animals that appear clinically dehydrated, hypovolemic, or in shock should receive fluid therapy and stabilization before NSAID administration. If anti-inflammatory treatment is urgently needed in such animals, careful risk-benefit assessment and close monitoring are required.

Production stage restrictions may apply to tolfenamic acid use in certain situations. Specific product labels may contain warnings or contraindications regarding use in pregnant or lactating animals, and these should be followed. Animals intended for slaughter before the withdrawal time can elapse should not be treated with tolfenamic acid unless the treatment is essential and extended holding can be arranged. Very young animals with immature metabolic systems may require dose adjustment or may not be appropriate candidates for treatment, depending on the specific product and indication.

The concurrent use of tolfenamic acid with other NSAIDs is contraindicated due to significantly increased risk of adverse effects. Combining multiple NSAIDs does not provide additional therapeutic benefit but dramatically increases the likelihood of gastrointestinal ulceration, renal toxicity, and bleeding complications. Animals should not receive tolfenamic acid if they have been treated with another NSAID within the previous 24 to 48 hours, and NSAID therapy should never be overlapped or stacked. This prohibition applies to all NSAIDs including aspirin, flunixin, meloxicam, ketoprofen, and others.

The interaction between tolfenamic acid and corticosteroids is clinically significant and potentially dangerous. Concurrent administration of these two drug classes substantially increases the risk of gastrointestinal ulceration, as both reduce protective mechanisms in the gastrointestinal tract through different pathways. If treatment with both an NSAID and corticosteroid is considered necessary, they should be separated in time, with appropriate washout periods between drugs. Veterinary supervision is essential when managing cases that might benefit from both anti-inflammatory drug classes.

Tolfenamic acid may interact with drugs that affect renal function or coagulation. Aminoglycoside antibiotics are nephrotoxic and should be combined with tolfenamic acid cautiously, with attention to adequate hydration and monitoring of kidney function. Anticoagulant medications, though uncommonly used in food animals, would have enhanced bleeding risk when combined with NSAIDs due to effects on platelet function. Diuretic medications may interact through effects on fluid balance and renal function, and animals receiving diuretics concurrently with tolfenamic acid should be monitored for dehydration.

Highly protein-bound drugs may interact with tolfenamic acid through displacement from plasma protein binding sites. Like other NSAIDs, tolfenamic acid binds extensively to plasma proteins, and concurrent administration with other highly bound medications could increase free drug concentrations of either agent. Sulfonamide antibiotics, commonly used in food animal medicine, are highly protein bound and represent a potential interaction concern. While clinically significant interactions from protein binding displacement are relatively uncommon, awareness of this possibility is warranted when multiple medications are prescribed.

Human safety precautions should be observed when handling and administering tolfenamic acid to livestock. Individuals with known hypersensitivity to NSAIDs should avoid direct contact with the product and should wear protective gloves during handling and administration. Accidental self-injection is a risk with any injectable medication, and proper animal restraint and careful injection technique help prevent such incidents. In the event of accidental self-injection, medical attention should be sought immediately, and the product label or safety data sheet should be provided to the treating physician.

Food safety and residue avoidance are paramount concerns when using tolfenamic acid in food-producing animals. Withdrawal times must be strictly observed, and producers must maintain accurate records of all treatments including animal identification, treatment date, dose administered, and withdrawal expiration date. Animals must not be sent for slaughter, and milk must not be sold for human consumption, until appropriate withdrawal periods have elapsed. When tolfenamic acid is used in an extra-label manner or when label guidance is unclear, consultation with a veterinarian or the Food Animal Residue Avoidance Databank is necessary to establish appropriate withdrawal intervals.

Environmental considerations include proper disposal of unused medication and contaminated materials. Empty vials and containers should be disposed of according to local regulations for pharmaceutical waste. Unused medication should not be poured down drains or disposed of in regular trash. Needles and syringes should be placed in approved sharps containers. While tolfenamic acid is not considered highly environmentally persistent, responsible disposal practices minimize any potential environmental impact.

Judicious use principles require that tolfenamic acid be used appropriately and only when indicated. Pain management is an important component of animal welfare, but NSAID therapy should not substitute for proper diagnosis and treatment of underlying conditions. Animals receiving tolfenamic acid should be monitored for clinical response, and failure to improve should prompt diagnostic reassessment rather than simply continuing or escalating anti-inflammatory therapy. Treatment duration should be limited to the minimum necessary for clinical improvement.

Documentation and veterinary oversight are essential for proper use of tolfenamic acid in food animals. A valid veterinarian-client-patient relationship must be established before the drug is prescribed. Treatment records should be maintained and available for inspection as required by local regulations. Any adverse effects observed should be documented and reported to the veterinarian. The veterinarian should provide clear instructions regarding dosing, administration technique, and withdrawal time observance.

Tolfenamic acid injectable solutions should be stored according to manufacturer specifications, typically at controlled room temperature between 15 and 25 degrees Celsius. The product should be protected from light and kept in the original container until use. Freezing should be avoided, as this may cause precipitation or other changes that affect product stability. Before administration, the solution should be visually inspected for particulates, discoloration, or other abnormalities, and any product that appears unusual should not be used.

Multi-dose vials require careful handling to maintain sterility and product quality throughout the use period. Aseptic technique should be employed when withdrawing doses, using sterile needles each time the vial septum is penetrated. The date of first use should be recorded on the vial, and the product should be discarded after the timeframe specified by the manufacturer, typically 28 days after first puncture. Needles should never be left in the vial septum between uses. Any vials showing signs of contamination, cloudiness, or precipitation should be discarded.

Disposal of tolfenamic acid products and related materials should follow local regulations for pharmaceutical waste. Unused medication should be disposed of through appropriate channels rather than discarded in regular trash or poured into drains. Empty vials may require specific disposal procedures depending on local regulations. Sharps including needles and syringes must be placed in approved sharps disposal containers. Product safety data sheets should be maintained and available for reference regarding specific storage, handling, and disposal requirements.

Species-specific dosing considerations apply when using tolfenamic acid across different livestock species. Cattle receive the standard dose of 2 mg per kilogram, with attention to accurate weight determination for proper dosing. Both beef and dairy cattle may be treated, though withdrawal time management differs significantly between these production types. Dairy cattle require careful attention to milk withdrawal periods to prevent residue violations, while beef cattle management focuses on meat withdrawal. Young calves may be treated at appropriate weight-adjusted doses, but very young animals should be evaluated individually.

Swine dosing follows similar guidelines to cattle, but administration considerations differ due to pig anatomy and handling characteristics. The intramuscular route is standard in pigs, with injection typically given in the neck region. Accurate weighing of pigs ensures proper dosing, particularly in young or growing animals where weight changes rapidly. Different production stages including nursery, growing, finishing, and breeding may have different practical considerations for treatment timing and withdrawal management.

Production type significantly influences tolfenamic acid use decisions. Dairy cattle operations must carefully manage milk withdrawal to prevent residue violations and maintain market access. Treatment of lactating dairy cows requires documentation and diversion of milk during the withdrawal period. Beef cattle operations focus on meat withdrawal, with treatment timing planned around anticipated marketing dates. Breeding animals, including both males and females, may be treated for appropriate indications, though any potential reproductive effects should be considered.

Breed differences within species generally have less impact on tolfenamic acid therapy than species differences, but individual variation exists. Some breeds or genetic lines may have different body compositions that affect drug distribution, though clinically significant breed-specific differences are not well documented. More important than breed is the individual animal's health status, with attention to hydration, kidney function, and concurrent medications. Geriatric animals and those with chronic health conditions may require modified treatment approaches or closer monitoring.

Several other NSAIDs are available for food animal use and may be considered as alternatives to tolfenamic acid depending on availability, indication, and regional approval status. Meloxicam is widely used and has become a standard NSAID in food animal practice, offering COX-2 preferential activity and extended duration of action. Flunixin meglumine has a long history of use in cattle and pigs, with well-established efficacy for respiratory disease and other inflammatory conditions. Ketoprofen is approved for food animals in many regions and provides another alternative when tolfenamic acid is unavailable or contraindicated.

Within the fenamate class, tolfenamic acid is the primary representative used in food animal medicine. Mefenamic acid and flufenamic acid are related compounds used in human medicine but not commonly employed in livestock. The fenamate class shares the basic mechanism of cyclooxygenase inhibition with other NSAIDs but may have somewhat different potency and selectivity profiles that contribute to variation in clinical effects and side effect patterns among different NSAID drugs.

Combination approaches to pain management may enhance the effectiveness of tolfenamic acid therapy. Local anesthetics provide immediate pain relief when administered at surgical sites or nerve blocks and can be combined with tolfenamic acid for comprehensive procedural pain management. The combination of immediate local anesthetic effect with extended NSAID analgesia represents current best practice for painful procedures. Other systemic analgesics may be employed in specific situations under veterinary supervision, though combining multiple systemic anti-inflammatory drugs is generally contraindicated due to increased toxicity risk.